Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 220

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

A genetics-led approach defines the drug target landscape of 30 immune-related traits

Open access
The ULTRA-DD Consortium, Fang, Hai, De Wolf, Hans, Knezevic, Bogdan, Burnham, Katie L., Osgood, Julie, Sanniti, Anna, Lledó Lara, Alicia, Kasela, Silva, De Cesco, Stephane, Wegner, Jörg K., Handunnetthi, Lahiru, McCann, Fiona E., Chen, Liye, Sekine, Takuya, Brennan, Paul E., Marsden, Brian D., Damerell, David, O’Callaghan, Chris A., Bountra, Chas, Bowness, Paul, Sundström, Yvonne, Milani, Lili, Berg, Louise, Göhlmann, Hinrich W., Peeters, Pieter J., Fairfax, Benjamin P., Sundström, Michael, Knight, Julian C. · 2019 · Nature Genetics

Abstract

Most candidate drugs currently fail later-stage clinical trials, largely due to poor prediction of efficacy on early target selection1. Drug targets with genetic support are more likely to be therapeutically valid2,3, but the translational use of genome-scale data such as from genome-wide association studies for drug target discovery in complex diseases remains challenging4–6. Here, we show that integration of functional genomic and immune-related annotations, together with knowledge of network connectivity, maximizes the informativeness of genetics for target validation, defining the target prioritization landscape for 30 immune traits at the gene and pathway level. We demonstrate how our genetics-led drug target prioritization approach (the priority index) successfully identifies current therapeutics, predicts activity in high-throughput cellular screens (including L1000, CRISPR, mutagenesis and patient-derived cell assays), enables prioritization of under-explored targets and allows for determination of target-level trait relationships. The priority index is an open-access, scalable system accelerating early-stage drug target selection for immune-mediated disease. A genetics-led translational approach integrating functional genomic predictors, knowledge of network connectivity and immune ontologies defines the drug target prioritization landscape for 30 immune traits at the gene and pathway level.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41588-019-0456-1

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Cited by

See all 220

Metadata

Authors
The ULTRA-DD Consortium, Fang, H., De Wolf, H., Knezevic, B., Burnham, K. L., Osgood, J., Sanniti, A., Lledó Lara, A., Kasela, S., De Cesco, S., Wegner, J. K., Handunnetthi, L., McCann, F. E., Chen, L., Sekine, T., Brennan, P. E., Marsden, B. D., Damerell, D., O’Callaghan, C. A., Bountra, C., Bowness, P., Sundström, Y., Milani, L., Berg, L., Göhlmann, H. W., Peeters, P. J., Fairfax, B. P., Sundström, M., & Knight, J. C.
Venue
Nature Genetics
Published
2019-06-28
Volume
51
Issue
7
Pages
1082-1091
ISSN
  • 1061-4036 (ISSN-L)
  • 1546-1718
OpenAlex
W2953945894
Cited by
220
References
21
FWCI
18.66
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A genetics-led approach defines the drug target landscape of 30 immune-related traits. https://app.cochat.ai/papers/10.1038/s41588-019-0456-1
The paper
The ULTRA-DD Consortium, Fang, H., De Wolf, H., Knezevic, B., Burnham, K. L., Osgood, J., Sanniti, A., Lledó Lara, A., Kasela, S., De Cesco, S., Wegner, J. K., Handunnetthi, L., McCann, F. E., Chen, L., Sekine, T., Brennan, P. E., Marsden, B. D., Damerell, D., O’Callaghan, C. A., . . . Knight, J. C. (2019). A genetics-led approach defines the drug target landscape of 30 immune-related traits. Nature Genetics. https://doi.org/10.1038/s41588-019-0456-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.